Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

June 17, 2002 17 June, 2002

UK's Largest Healthcare Retailer to Distribute Pheromone's Fertility Monitor

Pheromone Sciences Signs First Commercialization Agreement

Toronto, Ontario (June 17, 2002) -- Pheromone Sciences Corp. (TSX Venture Exchange:PHS), a Toronto- based biotech R & D company with proprietary technology in the field of non-invasive fertility and ovulation detection and Tri-Vision International Ltd./Lt�©e (TSX:TVL), a consumer electronics and marketing company with special retail relationships across the UK are pleased to announce the signing of a Letter of Intent (LOI) for the distribution of Pheromone's PSC Fertility Monitor(tm) in the United Kingdom. The LOI is expected to be followed by a definitive Distribution Agreement. The distribution agreement is to provide for the sale of the PSC Fertility Monitor exclusively in Boots Company PLC across the United Kingdom over a three-year period.

Boots is the UK's largest retailer of health products in the United Kingdom with over 1,400 retail outlets and a strong Internet based pharmacy network. Under the proposed distribution agreement Boots would be committed to selling a significant number of units of the product during each year. The product is expected to be available in Boots outlets before year-end.

The PSC Fertility Monitor is a fertility cycle monitoring device for the consumer and professional medical market. The PSC Fertility Monitor looks to set a new benchmark in providing a reliable "predictive" approach to natural, cycle-based family planning. The PSC Fertility Monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio-sensing and computer technologies. These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

As demonstrated in the recent US trial, the PSC Fertility Monitor detected more days of the conception window (the days when sexual intercourse can lead to a pregnancy) than the LH test strip product or the basal body temperature method. This determination, coupled with the published literature on the chances of conception during this window strongly suggests that women who use the PSC Fertility Monitor as a means of identifying their fertile window to time intercourse, can expect a substantially higher probability of conception or a substantially shorter time to pregnancy than if they relied solely on home based LH test kits as a means to time intercourse.

"The signing of this "LOI" represents a significant step in the execution of our commercialization strategy, stated Christopher Neuman", President and CEO of Pheromone. "Much effort has been put into the development of our Fertility Monitor technology and this solid expression of interest from one of the world's leading health care retailing organizations is a validation of our efforts to bring this technology to couples around the world."

This business agreement is the first for Tri- Vision's newly established Tri-Vision Technologies International Inc. subsidiary, which was created for the development and marketing of innovative technologies.

"While this is our first endeavor in delivering new technologies for other companies, our core business has been operating internationally for years and we continue to show success with our V-chip licensing to internationally-based television manufacturers. This relationship with Pheromone and Boots is a clear demonstration of Tri-Vision Technologies ability to market internationally." stated Tri-Vision Technologies President Toshginori Ikebe.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and do not accept responsibility for the adequacy or the contents of this news release.